Pembrolizumab clinical trials immune checkpoint inhibition

MK-3475 - Keytruda - lambrolizumab

Gastric or gastro-oesophageal junction cancer (advanced)

2 trials  - Keynote 061 - KEYNOTE-059

Head and neck cancer

3 trials  - Keynote 147 - KEYNOTE-040 - KEYNOTE-048

Lung cancer (metastatic)

All type of patients:  9 trials  - Keynote 042 (>=1%) - Keynote 042 (>=20%) - Keynote 042 (>=50%) - Keynote 189 - Keynote 407 - KEYNOTE-021 phase 2 - Keynote 010 10mg - Keynote 010 2mg - Keynote 024

First line:  6 trials  - Keynote 042 (>=1%) - Keynote 042 (>=20%) - Keynote 042 (>=50%) - Keynote 189 - KEYNOTE-021 phase 2 - Keynote 024

Second line :  2 trials  - Keynote 010 10mg - Keynote 010 2mg

Melanoma

Adjuvant 1 - NOVARTIS:  1 trials  - KEYNOTE-054

Adjuvant setting:  1 trials  - KEYNOTE-054

Adjuvant stage III only - NOVARTIS :  1 trials  - KEYNOTE-054

All type of patients:  6 trials  - KEYNOTE-054 - KEYNOTE 002 (10mg/kg Q3W) - KEYNOTE 002 (2mg/kg Q3W) - KEYNOTE-006 (every 2W) - KEYNOTE-006 (every 3W) - KEYNOTE-001

First line :  2 trials  - KEYNOTE-006 (every 2W) - KEYNOTE-006 (every 3W)

Second line (or later):  3 trials  - KEYNOTE 002 (10mg/kg Q3W) - KEYNOTE 002 (2mg/kg Q3W) - KEYNOTE-001

Multiple myeloma

2 trials  - KEYNOTE-183 - KEYNOTE-185

Renal-cell carcinoma (advanced)

1 trials  - KEYNOTE-426

Urothelial carcinoma (advanced)

4 trials  - KEYNOTE-045 - KEYNOTE-052 - Keynote 361 combination - Keynote 361 monotherapy